About Antiverse
Antiverse is a Healthcare company based in Cardiff (United Kingdom) founded in 2017 by Murat Tunaboylu and Ben Holland. An AI platform for antibody drug discovery is provided. Antiverse has raised $18.88 million across 7 funding rounds from investors including Syndicate Room, Development Bank of Wales and AngelHub. The company has 7 employees. Its chief executive, as recorded, is Murat Tunaboylu. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is ANTIVERSE LTD.
Company details
Antiverse was founded in 2017 and is headquartered in Cardiff, United Kingdom. Operations center on the biotechnology sector, where an AI-based platform is utilized for antibody drug discovery. Machine learning techniques are applied to predict antibody-antigen binding. Services include the development of antibody drug candidates, phage technology integration, 3D imaging analysis, customized data generation, sequence detection, and computational biology tools.
- Headquarters Cardiff, United Kingdom
- Employees 7
- Founders Murat Tunaboylu, Ben Holland
- SectorsHealthcare
- Email••••••••
- Website antiverse.io
- Social LinkedIn X
- Legal Name Antiverse Ltd
- Date of Incorporation 24 Apr, 2017
- Jurisdiction CARDIFF, WALES
- Total Equity Funding$18.88M (USD)
in 7 rounds
- Latest Funding Round$9.3M (USD), Series A
Mar 2026
- InvestorsSyndicate Room
& 17 more
- Employee Count7
Funding Insights of Antiverse
Antiverse has successfully raised a total of $18.88M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $9.3 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.88M
- Total Rounds 7
- Last Round Series A — $9.3M
- First Round $91,771
(Jun 2018)
- Investors Count 18
All 7 funding rounds of Antiverse with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $9.3M | Series A | – | Soulmates Ventures | |
| Oct 2024 | $4.58M | Seed | – | i&i Bio, Kadmos Capital | |
| Mar 2023 | $3.02M | Seed | – | Innospark, AngelHub | |
| Mar 2021 | $1.95M | Seed | – | Development Bank of Wales, ACF Investors | |
| Aug 2018 | Seed | – | – | – | |
| Jul 2018 | $26,308 | Seed | – | Babraham Research Campus | – |
| Jun 2018 | $91,771 | Grant | – | – |
18 investors in total: 16 institutional and 2 angel.
Investors in Antiverse
Antiverse has secured backing from 18 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Syndicate Room, Development Bank of Wales and AngelHub.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| inibio.eu | ||||
Investments in technology companies are made by Kadmos Capital. | kadmoscapital.com | London, United Kingdom | ||
Venture capital firm focused on AI, healthcare, life science, B2B enterprise, and technology sectors | innospark.vc | Boston, United States | ||
Early-stage innovations are funded by UKI2S across key sectors. | ukinnovationscienceseedfund.co.uk | Manchester, United Kingdom | ||
Tensor Ventures is focused on deep tech startup investments. | tensor.ventures | Senningerberg, Luxembourg | ||
High-impact science ventures are created by Deep Science Ventures. | deepscienceventures.com | |||
Provider of equity funding and business & property development loans | 2001 | developmentbank.wales | Wrexham, United Kingdom | |
Venture capital firm focused on angel investments | acfinvestors.com | Sheffield, United Kingdom | ||
Venture capital firm investing in seed & early-stage startups | wrencapital.co.uk | London, United Kingdom | ||
Angel network investing in the UK | 2002 | cambridgeangels.com | Cambridge, United Kingdom |
Investor details for Antiverse
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Antiverse
8 people are tracked at Antiverse (4 in leadership, 4 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Murat Tunaboylu | Co-Founder & CEO | Leadership |
Ben Holland | Co-Founder | Leadership |
Michael Mahdavi | Associate Director, Business Development | Leadership |
Ben H. | Co-founder/CTO | Leadership |
Ryan Emerson | ML Engineer | Team |
Andrew Moyes | Senior ML Engineer | Team |
Serbulent Unsal | Senior ML Engineer | Team |
Kirsty Greenow | Portfolio Manager | Team |
Complete people profiles for Antiverse
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Antiverse
3 dated milestones of Antiverse across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Antiverse is founded.
- Funding First funding round of $92K.
- Funding Latest funding round, Series A, of $9.3M.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Antiverse (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Antiverse
Complete news archive for Antiverse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antiverse
Antiverse was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Antiverse is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
Murat Tunaboylu is the CEO of Antiverse, as recorded in our data. They have also founded this company.
Antiverse is a funded company, having raised a total of $18.88M across 7 funding rounds to date. The company's 1st funding round was a Grant of $91.77K, raised on Jun 2018.
Antiverse has 7 employees.
Antiverse was founded in 2017 and is headquartered in Cardiff, United Kingdom. Operations center on the biotechnology sector, where an AI-based platform is utilized for antibody drug discovery. Machine learning techniques are applied to predict antibody-antigen binding. Services include the development of antibody drug candidates, phage technology integration, 3D imaging analysis, customized data generation, sequence detection, and computational biology tools.
Antiverse has 18 investors. Key investors include Syndicate Room, Development Bank of Wales, AngelHub, Cambridge Angels, and i&i Bio.
Antiverse operates through Antiverse Ltd.